Maze Therapeutics’ (MAZE) “Buy” Rating Reaffirmed at BTIG Research

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a note issued to investors on Tuesday, Benzinga reports. They presently have a $46.00 price objective on the stock. BTIG Research’s price objective indicates a potential upside of 76.58% from the company’s previous close.

MAZE has been the subject of several other research reports. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Four research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average price target of $63.40.

Maze Therapeutics Price Performance

Shares of MAZE traded down $0.16 during mid-day trading on Tuesday, hitting $26.05. 925,607 shares of the company were exchanged, compared to its average volume of 664,017. Maze Therapeutics has a 1-year low of $21.95 and a 1-year high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The company has a 50 day moving average of $27.16 and a 200-day moving average of $29.04. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -10.34 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76). Analysts expect that Maze Therapeutics will post -2.72 EPS for the current fiscal year.

Insider Buying and Selling at Maze Therapeutics

In related news, CMO Harold Bernstein sold 9,705 shares of the company’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $26.22, for a total transaction of $254,465.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Courtney Phillips sold 2,012 shares of the business’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12. Following the completion of the transaction, the insider owned 7,007 shares in the company, valued at $182,252.07. The trade was a 22.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 191,459 shares of company stock worth $5,263,539 in the last 90 days. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Maze Therapeutics

Hedge funds have recently made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Maze Therapeutics in the second quarter valued at approximately $48,000. Royal Bank of Canada grew its position in Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after acquiring an additional 1,383 shares during the period. Quantbot Technologies LP purchased a new position in Maze Therapeutics in the second quarter worth approximately $80,000. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics in the fourth quarter worth approximately $145,000. Finally, IFP Advisors Inc purchased a new position in Maze Therapeutics in the fourth quarter worth approximately $146,000.

Key Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Citigroup issued bullish coverage. A correction clarified that Citi initiated Maze Therapeutics with a “Buy” rating and a $50 price target, implying substantial upside from recent levels. Citi subsequently upgraded the stock to “Strong Buy.” Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target
• Positive Sentiment: Additional analysts also see significant upside. BTIG initiated coverage with a “Buy” rating and a $50 target, while HC Wainwright reaffirmed its “Buy” rating and maintained a $110 target—more than four times the recent share price. BTIG Initiates Maze Therapeutics at Buy With $50 Price Target HC Wainwright Reaffirms Buy Rating
• Positive Sentiment: Wedbush rated the company “Outperform.” The additional constructive view reinforces the broader analyst optimism surrounding Maze’s prospects. Maze Therapeutics Earns Outperform Rating from Wedbush
• Neutral Sentiment: Reported short interest was zero shares. The September 24 report listed no shares sold short and a 0.0-day short-interest ratio. This could reduce evidence of bearish positioning, although the figure may reflect a reporting or data issue given the accompanying reference to a large increase in short interest. Maze Therapeutics Shares Moved, So What Is Driving Attention Now?

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.